Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology

Recruiting now · Not applicable

Conditions studied: Radiosensitivity, Pediatric Cancer, Radiation Toxicity

In brief

Analysis of the individual radiosensitivity in pediatric oncology

Key facts

Study ID

NCT06033183

Run by

Neolys

People needed

100

Starts

2023-12-02

Expected to finish

2027-10-30

Last updated by the study team

2024-11-22

Who can join

Age: 3 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
• Children or adolescents > 3 years old and < 18 years old
• Patient with an indication for radiotherapy as part of the primary tumor local control strategy
• Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
• Patient affiliated with a social security scheme
• Patient and/or parents or holders of parental authority having dated and signed an informed consent

You may not qualify if…

• Patients with contraindications to blood sampling
• Patients with contraindications to radiotherapy
• Palliative radiotherapy
• Patient with previous RT treatment in the same area (re-irradiation)
• Patient with an indication of hypofractionated RT
• Patient follow-up not possible
• Persons deprived of liberty or under guardianship (including curatorship)
• Exclusion Criteria:

Where it is running

• Centre François Baclesse — Caen, France (enrolling)
• Centre Oscar Lambret — Lille, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.